The fibroblast growth factor 21 concentration in children with mitochondrial disease does not depend on the disease stage, but rather on the disease genotype
Dorota Wesół‐Kucharska(Children's Memorial Health Institute), Aleksandra Jezela‐Stanek, Edyta Czekuć-Kryśkiewicz(Children's Memorial Health Institute), Maciej Jaworski(Children's Memorial Health Institute), Dorota Piekutowska‐Abramczuk(Children's Memorial Health Institute), Elżbieta Ciara(Children's Memorial Health Institute), Dariusz Rokicki(Children's Memorial Health Institute), Magdalena Kaczor(Children's Memorial Health Institute), Milena Greczan(Children's Memorial Health Institute), Paulina Halat-Wolska(Children's Memorial Health Institute)
Cited by 1
Related Papers
Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia
|Journal of the American Society of Nephrology|2015|284
New perspective in diagnostics of mitochondrial disorders: two years’ experience with whole-exome sequencing at a national paediatric centre
|Journal of Translational Medicine|2016|233
Clinical implementation of RNA sequencing for Mendelian disease diagnostics
|Genome Medicine|2022|215
Biallelic mutations in CYP24A1 or SLC34A1 as a cause of infantile idiopathic hypercalcemia (IIH) with vitamin D hypersensitivity: molecular study of 11 historical IIH cases
|Journal of Applied Genetics|2017|94
Frequency gradients of DHCR7 mutations in patients with Smith-Lemli-Opitz syndrome in Europe: evidence for different origins of common mutations
|European Journal of Human Genetics|2001|71